What we do
Artificial Intelligence (AI) driven therapeutic decision-making tool
Focus
Developing algorithms in prostate cancer (PCa) and diabetic foot ulcers (DFUs) to help choose optimal treatment for a patient
PD Theranostics Inc. (PDTx), a Laidlaw Venture Partners portfolio company operating under Laidlaw & Company UK Ltd., develops AI-guided algorithmic tools for healthcare professionals. Founded in 2018, the company aims to use image-based methods to diagnose and guide therapeutic decision-making for specific human diseases including cancer, infectious diseases, and diabetes-related complications. The platform is designed to determine both the severity of the disease as well as the optimal treatment decision, all through AI capabilities.
Recent developments at PH Theranostics include the closing of series A round funding, the installment of the Hyperion Imaging Mass Cytometry (IMC) system to further increase on-hand AI data, IMC data integration with Mass Spectroscopy data to define clinical courses and treatments, and the accumulation of promising data regarding prostate cancer and diabetic foot conditions.
CEO Patrick Gallagher leads the PD Theranostics team, with President Matthew Duffy and Director James Ahern, all of whom are also Managing Partners at Laidlaw Venture Partners. The office is located across the street from the Vaccine and Immunotherapy Center (VIC) at Mass General in Charlestown, Massachusetts, where the teams are in constant communication.
